Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gusperimus versus conventional therapy for relapse of granulomatosis with polyangiitis
2011-001219-30Phase 3Completed
- Sponsor
- Nordic Pharma
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of deoxyspergualin in granulomatosis with polyangiitis (GPA) (2 arms), sponsored by Nordic Pharma. Primary endpoint: Primary efficacy endpoint. Started Jun 2011; status: completed.
02
Drugs
deoxyspergualin
03
Conditions
granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on 2011-001219-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001219-30.